The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDXG | +18.25% | +5.64% | +1.1% | +32% |
| S&P | +15.06% | +95.03% | +14.29% | +420% |
MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.
The company released data for two drug programs and missed its goals on both.
The company's shares are being delisted from the Nasdaq exchange tomorrow.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $98.61M | 13.1% |
| Gross Profit | $79.82M | 10.6% |
| Gross Margin | 80.95% | -1.8% |
| Market Cap | $902.46M | -11.8% |
| Market Cap / Employee | $1.08M | 0.0% |
| Employees | 837 | -6.5% |
| Net Income | $9.62M | -45.4% |
| EBITDA | $15.53M | -35.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $118.87M | 72.2% |
| Accounts Receivable | $69.23M | 31.1% |
| Inventory | 24.9 | -0.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $17.21M | -5.7% |
| Short Term Debt | $1.25M | 25.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 12.26% | -30.3% |
| Return On Invested Capital | -0.61% | 9.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $14.24M | -34.4% |
| Operating Free Cash Flow | $14.42M | -33.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 10.10 | 33.81 | 28.18 | 28.33 | 140.06% |
| Price to Book | 4.80 | 7.81 | 5.78 | 4.45 | -32.25% |
| Price to Sales | 2.56 | 4.12 | 3.23 | 2.51 | -17.25% |
| Price to Tangible Book Value | 5.78 | 9.40 | 6.89 | 5.24 | -36.64% |
| Price to Free Cash Flow TTM | 16.02 | 22.25 | 17.31 | 15.67 | -27.98% |
| Enterprise Value to EBITDA | 65.98 | 113.91 | 91.65 | 52.27 | 28.89% |
| Free Cash Flow Yield | 6.2% | 4.5% | 5.8% | 6.4% | 38.85% |
| Return on Equity | 62.5% | 25.0% | 22.3% | 16.6% | -76.19% |
| Total Debt | $19.02M | $24.84M | $18.66M | $18.46M | -4.09% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
